University of Illinois at Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Illinois at Chicago sits in the top decile of US sponsors by registered trial count (#83 of 15,742 sponsors by registered trial count).

430 total trials 115 currently recruiting 236 completed early-phase tilt top decile by trial count

University of Illinois at Chicago: 430 sponsored US clinical trials, 115 recruiting.

University of Illinois at Chicago sponsors 430 registered US clinical trials on ClinicalTrials.gov, 115 of them currently recruiting, and 236 completed. 30 of these trials are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 10 trials.

Top-decile sponsor footprint

University of Illinois at Chicago ranks in the top decile of sponsors by registered trial count (#83 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 57/100

236 of 271 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

430 total, page 9 of 9

COMPLETED Phase 4

Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care

NCT01005602

COMPLETED Phase 2

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

NCT00765479

COMPLETED Phase 4

The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers

NCT00594867

COMPLETED NA

A Pilot Observational Clinical Survey: Impacts of Tahitian Noni Juice on the Quality of Life of Patients With Osteoarthritis

NCT01070264

TERMINATED Phase 2

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NCT00845845

COMPLETED Phase 2

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026

COMPLETED NA

A Randomized Controlled Trial of Mental Health Peer-Led Education

NCT01297985

TERMINATED Phase 4

Intrapulmonary Pharmacokinetics of Antibiotics

NCT00315601

COMPLETED Phase 2

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555

COMPLETED Phase 4

Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

NCT00716586

COMPLETED Phase 3

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

NCT00148083

COMPLETED NA

School-Based Mental Health Services for Urban Children

NCT00612690

COMPLETED Phase 2

Polestriding Versus Walking for Subjects With Poor Leg Circulation

NCT00719355

COMPLETED NA

Evaluation of a Youth Mentoring Program

NCT00158353

COMPLETED NA

Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents

NCT00592202

COMPLETED Phase 1

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813

COMPLETED NA

Cost Effective Health Promotion for Older Adults

NCT00953030

COMPLETED Phase 1

Lycopene in Preventing Prostate Cancer in Healthy Participants

NCT00093561

COMPLETED

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

NCT00490464

COMPLETED Phase 2

Lamotrigine Monotherapy in Pediatric Bipolar Disorder

NCT00176228

COMPLETED Phase 1

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

NCT00242177

COMPLETED Phase 2

Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)

NCT01057797

COMPLETED Phase 3

Duragen Versus Duraguard in Chiari Surgery

NCT00741858

COMPLETED Phase 3

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

NCT00176202

COMPLETED NA

The Measurement of Empathy and Its Efficacy in Psychotherapy

NCT00620009

COMPLETED NA

Walking Intervention in African American Adults With Newly Diagnosed Hypertension

NCT00298207

COMPLETED Phase 1

Lycopene In Preventing of Prostate Cancer

NCT00006078

COMPLETED NA

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

NCT01499147

COMPLETED Phase 4

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

NCT00663442

COMPLETED Phase 2

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00003568

← Previous Page 9 of 9

Phase Distribution

PhaseTrial count
Phase 1 37
Phase 2 43
Phase 3 11
Phase 4 19

What is open in the University of Illinois at Chicago pipeline

115 recruiting of 430 indexed (27% open); 236 completed (55%).

Phase mix: 30 late (III/IV) vs 80 early (I/II) (early-phase heavy).

Top condition: Multiple Sclerosis (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Illinois at Chicago: open-pipeline peers nationwide

Peers matched on 430 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

University of Illinois at Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%10%20%30% Total trials Recruiting share University of Illinois at ChicagoVanderbilt UniversityChildren's Hospital of PhiladelphiaNovo Nordisk A/SDartmouth-Hitchcock Medical CenterCoherus OncologyNewAmsterdam PharmaPortland VA Medical CenterWhite River Junction Veterans Affairs Medical Center
University of Illinois at Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Illinois at Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 430 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

What to do with this University of Illinois at Chicago page

430 registered trials is a research-attention snapshot, not an endorsement of University of Illinois at Chicago or any single study.

  • 115 of University of Illinois at Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Multiple Sclerosis is the condition University of Illinois at Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Illinois at Chicago pipeline card: 430 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.